68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Somatostatin receptor(SSTR) was expressed in neuroendocrine tumor cells and SSTR-targeting
 molecular imaging(68Ga-DOTATATE PET/CT) could be a promising technique to evaluate the
 primary tumor and metastatic lesions of neuroendocrine tumors with higher accuracy. This
 prospective study is going to investigate whether radiolabeled somatostatin analogs
 68Ga-DOTATATE PET/CT may be valuable for diagnosis, risk stratification, and prognostic
 evaluation of neuroendocrine tumors and compared it with 18F-FDG PET/CT.
Neuroendocrine tumor(NET)can be derived from endocrine glands, endocrine tissues and
 endocrine cells from any parts of body. Due to its occult onset and heterogeneity, it is hard
 to be detected by conventional imaging like CT and it is often at late stage when diagnosed.
 New imaging modality such as 18F-FDG PET/CT have been well-accepted as a practical way to
 evaluate the aggressive of tumor. 18F-FDG PET/CT has been used to improve the efficacy in
 assessing the extent and severity of NET, but the diagnostic accuracy of 18F-FDG PET/CT
 decreased in low proliferation tumor cells and inflammation. Recent studies showed
 somatostatin receptor (SSTR) was expressed in NET cells and SSTR-targeting molecular
 imaging-68Ga-DOTATATE PET/CT could be a promising technique to evaluate the extent of NET
 with higher accuracy. Especially in some well differentiated tumor, 18F-FDG PET/CT can be
 negative, while 68Ga-DOTATATE PET/CT can be positive. However, the results can be varied in
 these two imaging modalities and characterized this disease at multiple levels such as
 clinical presentation, biologic characteristics, treatment response, and clinical
 outcome.This prospective study is going to investigate whether 68Ga-DOTATATE PET/CT may be
 superior to 18F-FDG PET/CT for diagnosis, risk stratification, and prognostic evaluation of
 NET.
Inclusion Criteria:

 -  suspected or confirmed untreated NET patients previously performed 18F-FDG PET/CT
 signed written consent.

 Exclusion Criteria:

 -  pregnancy breastfeeding known allergy against TATE any medical condition that in the
 opinion of the investigator, may significantly interfere with study compliance.